Pharmaceutical Commerce - November/December 2011 - (Page 12)

Business Finance A Conversation with Steve Collis, AmeriSourceBergen CEO Last summer, AmerisourceBergen effected a milestone transfer of leadership—from the company’s founding merger in 2001 under R. David Yost, to his successor, Steve Collis. Collis, a 17-year company veteran, had been president of AmerisourceBergen Specialty Group, and then COO of the entire corporation. AmerisourceBergen comprises Drug Corporation (ABDC), Specialty Group (ABSG), and Consulting Services (ABCS), with operations in the US, Canada and Great Britain. By Nicholas Basta Let’s start with a snapshot of AmerisourceBergen today; it appears to have been another good year in a string of good years for ABC’s business. Do you have a positive outlook for the year as a whole and going forward? AmerisourceBergen is wrapping up one of its strongest years ever with14-15% growth on top of 31% growth last year. That’s not to say we won’t have challenges in the coming years. Our long term growth hopes to have a 15% growth annually, but we will have to look for that growth from other places, particularly with our emphasis on operating margins and our strong balance sheet control. It will be an interesting and challenging year for us. As we stated in July, we expect 2012 to be a similarly good year, with many new generic introductions, and opportunities in specialty pharmaceuticals. We are implementing a new SAP system and are making changes to our approach in customer service, making it easier for our customers to do business with us. We expect those changes will enable us to offer new services and to capture value for our customers. Recently, we’ve made some new acquisitions and we expect to manage them well to offer more value for our manufacturer partners and maintain our productivity momentum. AmerisourceBergen is wrapping up one of its strongest years ever, with 30% growth in earnings, whereas we had been giving guidance expecting something like 10% growth. We won’t be able to sustain that indefinitely; our long term goal is to have 15% growth in earnings annually—and there’s not many large US companies today that can put up those sorts of numbers. It will be an interesting year for us. As we stated in July, we expect 2012 to be a similarly good year, with many new generic introductions, and opportunities in specialty pharmaceuticals. We are finishing the implementation of a new SAP system and expect that to enable us to offer new services and to capture value for our manufacturing clients. We have some new acquisitions and we expect to manage them well and maintain productivity momentum. You’ve taken the helm of ABC after 10 years of leadership by its founder, Dave Yost. What has the transition been like for you personally? In all sincerity, I have to give full credit to Dave who built the AmerisourceBergen business and created a strong team to manage it. Shortly after taking over, I participated in a new CEO program at Harvard University. One of the things we discussed is that the best management transitions occur when you promote from within. With our current management team, we are confident that we have the right people at the table—experienced, strong leaders who collaborate well. Collaboration is one of my key management tenets (see Table) and with managers like Dave Neu (ABDC) and Peyton Howell (ABCS) and James Frary (ABSG), we have many strengths. Collaboration means that we will take the best practices from one area, (such as our strong relationships in managing reimbursement in oncology) and apply that to other areas of our business. As CEO, I have learned that the old cliché is true—the buck stops with you. Ultimately it’s your judgment that has to be applied. But it takes us back to the need for collaboration. We make decisions at the table—together. Personally, my family and I moved from Texas (headquarters of AmerisourceBergen Specialty Group, which Collis headed prior to being promoted to COO) two years ago. We were very comfortable living in Texas for 14 years; and the living in Pennsylvania certainly has its appeal, but the first winter—was certainly different for us! My family has settled into the Philadelphia area and the community is welcoming. I have three children, two in high school and one in elementary school. We’re becoming involved in the community, partly through AmerisourceBergen’s community-relations efforts, which emphasize assisting in health-related areas. Very quickly after the transition, AmerisourceBergen announced three significant acquisitions (TheraCom, Premier Source and IntrinsiQ). Can you talk about the rationale for these acquisitions, and what they mean for pharma manufacturers? These acquisitions were in the works well before the transition, and come about through some serious diligence, hard but fair negotiations and the best value for our shareholders. All three companies are best-in-class and are exactly the sort of acquisitions that help differentiate us from our competition and offer a better value to our clients, both manufacturers and healthcare providers. TheraCom has extensive experience in outcomes, in general and in the pharmacy benefits management reimbursement field, and will give our existing capabilities in our consulting services, a new breadth and scope. IntrinsiQ helps oncologists with therapy decisions and appropriate care, and helps manufacturers with data on clinical Management Principles per Steve Collis outcomes and product utilization. Premier Source has expertise on market access for therapies and medical devices. > Collaborate to drive innovation for stakeholders Pharma manufacturers are dealing with much more complex commercialization practices, such as REMS (Risk Evaluation and Mitigation Strategies), molecular > Increase customer and supplier value diagnostics and biomarkers and the like. We have a good track record in bringing in acquisitions and making them strong collaborative resources for our clients, and we > Expand our business in targeted markets have high expectations for these acquisitions. > Maximize operating efficiency > Create and maintain a high-performance culture Do these acquisitions represent an expansion of AmerisourceBergen beyond distribution services? Will AmerisourceBergen become a bigger part of the overall healthcare ecosystem going forward? 12 November | December 2011 www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - November/December 2011

Pharmaceutical Commerce - November/December 2011
Contents
Editorial
Op-Ed
Top News
Business/Finance
Brand Marketing & Communications
Supply Chain/Logistics
Information Technology
Manufacturing & Packaging
Legal & Regulatory
Meetings and Editorial Index

Pharmaceutical Commerce - November/December 2011

http://www.nxtbook.com/nxtbooks/pharmcomm/201911
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com